

Curriculum Vitae

Personal information **Signe Schmidt**

Work experience

Nov 2025 - present	Danish Medicines Agency, Denmark (<i>specialist training in Clinical Pharmacology</i>)
Jan 2025 - Oct 2025	Dept of Clinical Pharmacology, Bispebjerg University Hospital, Denmark (<i>specialist training in Clinical Pharmacology</i>)
Nov 2023 - Dec 2024	General Practice, Bagsværd, Denmark (<i>specialist training in Clinical Pharmacology</i>)
May 2023 - Oct 2023	Steno Diabetes Center Copenhagen (SDCC), Denmark (<i>specialist training in Clinical Pharmacology</i>)
May 2022 - Apr 2023	Medical & Science, Novo Nordisk A/S, Denmark (<i>specialist training in Clinical Pharmacology</i>)
Feb 2021 - Jan 2022	Dept of Clinical Pharmacology, Bispebjerg University Hospital, Denmark (<i>specialist training in Clinical Pharmacology</i>)
Apr 2020 – present	Senior Researcher and Team Leader, Clinical Research, SDCC, Denmark (part time)
Feb 2019 – Mar 2020	Researcher, Clinical Research, SDCC, Denmark
May 2018 – Jan 2019	Post Doc, Clinical Research, SDCC, Denmark
Dec 2013 – Apr 2018	Post Doc, Dept of Endocrinology, Hvidovre University Hospital, Denmark – incl. 2 maternity leaves: 03/03/2015–14/01/16 & 22/03/2017–01/05/2018
Mar 2013 – Nov 2013	MD, Dept of Endocrinology, Hvidovre University Hospital, Denmark (<i>specialist training in Internal Medicine</i>)
Sep 2009 – Feb 2013	PhD Student, Dept of Endocrinology, Hvidovre University Hospital, Denmark
Jun 2009 – Aug 2009	MD, Sisimiut Sundhedscenter, Greenland
Sep 2008 – Jun 2009	MD, Dept of Accident and Emergency, Karolinska University Hospital, Sweden
Feb 2007 – Aug 2008	MD (residency), Storstrømmens Amt, Denmark

Education and training

Sep 2009 to May 2013 PhD, University of Copenhagen, Denmark

Jan 2000 to Jan 2007 Medical Doctor, University of Copenhagen, Denmark

Additional information

Publications

1. Ranjan AG, Schmidt S, Nørgaard K. Faster-acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non-automated insulin pump and continuous glucose monitoring-A double-blind randomized controlled crossover trial. *Diabetes Obesity and Metabolism*. 2025. doi: 10.1111/dom.16326

2. McCarthy O, Christensen MB, Tawfik S, Kristensen KB, Hartmann B, Holst JJ, Schmidt S, Nørgaard K, Bracken RM. Metabolic and Hormonal Responses to Isomaltulose Ingestion Before or During Sustained Submaximal Exercise in Adults with Type 1 Diabetes Using Automated Insulin Delivery Systems. *Nutrients*. 2024. doi: 10.3390/nu16234098
3. Shah V, Peter AL, Umpierrez GE, Sherr JL, Akturk HK, Aleppo G, Bally L, Cengiz E, Cinar A, Dungan K, Fabris C, Jacobs PG, Lal RA, Mader JK, Masharani U, Prahalad P, Schmidt S, Zijlstra, Ho CN, Ayers AT, Tian T, Aaron RE, Klonoff DC. Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System. *Journal of Diabetes Science and Technology*. 2024. doi: 10.1177/19322968241291512
4. Klonoff DC, Freckmann G, Pleus S, Kovatchev BP, Kerr D, Tse CC, Li C, Agus MSD, Dungan K, Voglová Hagerf B, Krouwer JS, Lee WAA, Misra S, Rhee SY, Sabharwal A, Seley JJ, Shah VN, Tran NK, Waki K, Worth C, Tian T, Aaron RE, Rutledge K, Ho CN, Ayers AT, Adler A, Ahn DT, Aktürk HK, Al-Sofiani ME, Bailey TS, Baker M, Bally L, Bannuru RR, Bauer EM, Bee YM, Blanchette JE, Cengiz E, Chase JG, Y Chen K, Cheriavsky D, Clements M, Cote GL, Dhatriya KK, Drincic A, Ejekjaer N, Espinoza J, Fabris C, Fleming GA, Gabbay MAL, Galindo RJ, Gómez-Medina AM, Heinemann L, Hermanns N, Hoang T, Hussain S, Jacobs PG, Jendle J, Joshi SR, Koliwad SK, Lal RA, Leiter LA, Lind M, Mader JK, Maran A, Masharani U, Mathioudakis N, McShane M, Mehta C, Moon S-J, Nichols JH, O'Neal DN, Pasquel FJ, Peters AL, Pfützner A, Pop-Busui R, Ranjekar P, Rhee CM, Sacks DB, Schmidt S, Schwaighofer SM, Sheng B, Simonson GD, Sode K, Spanakis EK, Spartano NL, Umpierrez GE, Vareth M, Vesper HW, Wang J, Wright E, Wu AHB, Yeshiwas S, Zilbermint M, Kohn MA. The Diabetes Technology Society Error Grid and Trend Accuracy Matrix for Glucose Monitors. *Journal of Diabetes Science and Technology*. 2024. doi: 10.1177/19322968241275701
5. Holmager P, Christensen MB, Nørgaard K, Schmidt S. GLP-1 Receptor Agonists in Overweight and Obese Individuals With Type 1 Diabetes Using an Automated Insulin Delivery Device: A Real-World Study. *Journal of Diabetes Science and Technology*. 2024. doi: 10.1177/19322968241289438
6. Richter MM, Kemp IM, Heebøll S, Winther-Sørensen M, Kjeldsen SAS, Jensen NJ, Nybing JD, Linden FH, Høgh-Schmidt E, Boesen MP, Madsbad S, Schiødt FV, Nørgaard K, Schmidt S, Gluud LL, Haugaard SB, Holst JJ, Nielsen S, Rungby J, NJW Albrechtsen. Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms. *Metabolism*. 2024. doi: 10.1016/j.metabol.2024.155915
7. Kjeldsen SAS, Richter MM, Jensen NJ, Nilsson MSD, Heinz N, Nybing JD, Linden FH, Høgh-Schmidt E, Boesen MP, Andersen TL, Johannesen HH, Trammell SAJ, Grevengeod TJ, Madsbad S, Vilstrup H, Schiødt FV, Møller A, Rashu EB, Nørgaard K, Schmidt S, Gluud LL, Haugaard SB, Holst JJ, Rungby J, Albrechtsen NJW. Glucagon Resistance in Individuals With Obesity and Hepatic Steatosis Can Be Measured Using the GLU-SENTIC Test and Index. *Diabetes*. 2024. doi: 10.2337/db23-0858
8. Christensen MB, Ranjan AG, Rytter K, McCarthy OM, Schmidt S, Nørgaard K. Automated insulin delivery in adults with type 1 diabetes and suboptimal HbA1c during prior use of insulin pump and continuous glucose monitoring: A randomized controlled trial. *Journal of Diabetes Science and Technology*. 2024. doi: 10.1177/19322968241242399
9. Lorenzen JT, Madsen KP, Cleal B, Joensen LE, Nørgaard K, Pedersen-Bjergaard U, Schmidt S, Rytter K, Willaing I. Associations between use of diabetes technology and diabetes distress: a Danish cross-sectional survey of adults with type 1 diabetes. *BMJ Open*. 2024. doi: 10.1136/bmjopen-2023-080053
10. Tian T, Aaron RE, DuNova AY, Jendle JH, Kerr D, Cengiz E, Drincic A, Pickup JC, Chen KY, Schwartz N, Muchmore DB, Akturk HK, Levy CJ, Schmidt S, Bellazzi R, Wu AHB, Spanakis EK, Najafi B, Chase JG, Seley JJ, Klonoff DC. Diabetes Technology Meeting 2023. *Journal of Diabetes Science and Technology*. 2024. doi: 10.1177/19322968241235205
11. Kristensen KB, Ranjan AG, McCarthy OM, Bracken RM, Nørgaard K, Schmidt S. Sensor-Based Glucose Metrics during Different Diet Compositions in Type 1 Diabetes—A Randomized One-Week Crossover Trial. *Nutrients*. 2024. doi: 10.3390/nu16020199
12. Kristensen KB, Ranjan AG, McCarthy OM, Holst JJ, Bracken RM, Nørgaard K, Schmidt S. Effects of a low-carbohydrate-high-protein pre-exercise meal in type 1 diabetes – a randomised, crossover trial. *The Journal of Clinical Endocrinology and Metabolism*. 2023. doi: 10.1210/clinem/dgad427
13. Kelly AS, Arslanian S, Hesse D, Iversen AT, Körner A, Schmidt S, Sørrig R, Weghuber D, Jastreboff AM. Reducing BMI below the obesity threshold in adolescents treated with once - weekly subcutaneous semaglutide 2.4 mg. *Obesity*. 2023. doi: 10.1002/oby.23808
14. Schmidt S, Madsen KP, Pedersen-Bjergaard U, Rytter K, Hommel E, Cleal B, Willaing I, Andersen HU, Nørgaard K. Associations between Clinical and Psychosocial Factors and HbA1c in Adult Insulin Pump Users with Type 1 Diabetes. *Acta Diabetologica*. 2023. doi: 10.1007/s00592-023-02081-4
15. Laugesen C, Ranjan A, Schmidt S, Nørgaard K. Pen-administered low-dose dasiglucagon versus usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a phase 2, randomised, open-label, 2-period crossover trial. *Diabetologia*. 2023. doi: 10.1007/s00125-023-05909-4
16. McCarthy OM, Christensen MB, Kristensen KB, Schmidt S, Ranjan A, Bain S, Bracken RM, Nørgaard K.

Automated insulin delivery around exercise in adults with type 1 diabetes: A pilot randomised controlled study. *Diabetes Technology & Therapeutics*. 2023. doi: 10.1089/dia.2023.0009

17. McCarthy OM, Christensen MB, Kristensen KB, Schmidt S, Ranjan A, Bain S, Bracken RM, Nørgaard K. Glycaemia around exercise in adults with type 1 diabetes using automated and non-automated insulin delivery pumps: A switch pilot trial. *Diabetes Technology & Therapeutics*. 2023. doi: 10.1089/dia.2022.0542
18. Rytter K, Madsen KP, Andersen HU, Hommel E, Pedersen-Bjergaard U, Schmidt S, Nørgaard K. Associations between insulin pump self-management and HbA1c in type 1 diabetes. *Diabetic Medicine*. 2023. doi: 10.1111/dme.15068
19. Kjeldsen SAS, Richter MM, Jensen NJ, Nilsson MSD, Heinzel N, Nybinge JD, Lindene FH, Høgh-Schmidt E, Boesen MP, Madsbad S, Vilstrup H, Schiødt FV, Møller, Nørgaard K, Schmidt S, Rashui EB, Gluud LL, Haugaard SB, Holst JJ, Rungby J, Albrechtsen NJW. Development of a glucagon sensitivity test in humans: Pilot data and the GLUSENTIC study protocol. *Peptides*. 2023. doi: 10.1016/j.peptides.2022.170938
20. McCarthy O, Kristensen KB, Christensen MB, Schmidt S, Ranjan AG, Nicholas C, Bain SC, Nørgaard K, Bracken R. Metabolic and physiological responses to graded exercise testing in individuals with type 1 diabetes using insulin pump therapy. *Diabetes, Obesity & Metabolism*. 2023. doi: 10.1111/dom.14938
21. Madsen KP, Olsen KR, Rytter K, Willaing I, Pedersen-Bjergaard U, Schmidt S, Nørgaard K, Kjær T. Effects of initiating insulin pump therapy in the real world: a nationwide, register-based study of adults with type 1 diabetes. *Diabetes Research and Clinical Practice*. 2023. doi: 10.1016/j.diabres.2022.110225
22. McCarthy O, Schmidt S, Christensen MB, Bain SC, Nørgaard K, Bracken R. The endocrine pancreas during exercise in people with and without type 1 diabetes: Beyond the beta-cell. *Frontiers in Endocrinology*. 2022. doi: 10.3389/fendo.2022.981723
23. Huang J, Yeung AM, Nguyen KT, Xu NY, Preiser J-C, Rushakoff RJ, Seley JJ, Umpierrez GE, Wallia A, Drincic T, Gianchandani R, Lansang MC, Masharani U, Mathioudakis N, Pasquel FJ, Schmidt S, Shah VN, Spanakis EK, Stuhr A, Treiber GM, Klonoff DC. Hospital Diabetes Meeting 2022. *Journal of Diabetes Science and Technology*. 2022. doi: 10.1177/19322968221110878
24. Laugesen C, Ranjan AG, Schmidt S, Nørgaard K. Low-Dose Dasiglucagon versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People with Type 1 Diabetes: A Phase 2, Randomized, 3-Arm Cross-Over Study. *Diabetes Care*. 2022. doi: 10.2337/dc21-2304
25. Rytter K, Madsen KP, Andersen HU, Cleal B, Hommel E, Nexø MA, Pedersen-Bjergaard U, Skinner T, Willaing I, Nørgaard K, Schmidt S. Insulin Pump Treatment in Adults with Type 1 Diabetes in the Capital Region of Denmark: Design and Cohort Characteristics of the Steno Tech Survey. *Diabetes Therapy*. 2022. doi: 10.1007/s13300-021-01181-0
26. Schmidt S, Frandsen CS, Dejgaard TF, Vistisen D, Halldórrsson T, Olsen SF, Jensen JEB, Madsbad S, Andersen HU, Nørgaard K. Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes. *Diabetes, Obesity & Metabolism*. 2022. doi: 10.1111/dom.14567
27. Braune K, Lal RA, Petruželková L, Scheiner G, Winterdijk P, Schmidt S, Raimond L, Hood KK, Riddell MC, Skinner TC, Raile K, Hussain S. Open-Source Automated Insulin Delivery: International Consensus Statement and Practical Guidance for Healthcare Professionals. *Lancet Diabetes and Endocrinology*. 2022. doi: 10.1016/S2213-8587(21)00267-9
28. Cleal B, Nexø MA, Schmidt S, Rytter K, Nørgaard K, Willaing I. Values and control in type 1 diabetes beyond glycemic outcomes: A qualitative interview study of everyday life with an insulin pump. *Chronic Illness*. 2022. doi: 10.1177/17423953211023962
29. Clausen HG, Knudsen T, Ahdab MA, Aradóttir TB, Schmidt S, Nørgaard K, Leth J. A New Stochastic Approach for Modeling Glycemic Disturbances in Type 2 Diabetes. *Transactions on Biomedical Engineering*. 2021. doi: 10.1109/TBME.2021.3074868
30. Steineck IIK, Ranjan A, Schmidt S, Nørgaard K. Time spent in hypoglycemia is comparable when the same amount of exercise is performed 5 or 2 days weekly: a randomized crossover study in people with type 1 diabetes. *BMJ Open Diabetes Research & Care*. 2021. doi: 10.1136/bmjdr-2020-001919
31. Laugesen C, Schmidt S, Holst JJ, Nørgaard K, Ranjan A. The effect of preceding glucose decline rate on low-dose glucagon efficacy in individuals with type 1 diabetes: A randomized crossover trial. *Diabetes, Obesity & Metabolism*. 2021. doi: 10.1111/dom.14301
32. Al-Sari N, Schmidt S, Suvitaival T, Kim M, Trost K, Ranjan AG, Christensen MB, Overgaard AJ, Pociot F, Nørgaard K, Legido-Quigley C. Changes in the lipidome in type 1 diabetes following low carbohydrate

diet: post-hoc analysis of a randomized crossover trial. *Endocrinology, Diabetes & Metabolism*. 2021. doi: 10.1002/edm2.213

33. Rytter K, Schmidt S, Rasmussen LN, Pedersen-Bjergaard U, Nørgaard K. Education programmes for persons with type 1 diabetes using an insulin pump: A systematic review. *Diabetes/Metabolism Research and Reviews*. 2021. doi: 10.1002/dmrr.3412
34. Christensen MB, Serifovski N, Herz AMH, Schmidt S, Hommel E, Raimond L, Perrild HJD, Gaede P, Nørgaard K. Efficacy of a bolus calculator and advanced carbohydrate counting in type 2 diabetes: A randomized clinical trial. *Diabetes Technology & Therapeutics*. 2021. doi: 10.1089/dia.2020.0276
35. Aradóttir TB, Bengtsson H, Jensen ML, Poulsen NK, Boiroux D, Jensen LL, Schmidt S, Nørgaard K. Feasibility of a New Approach to Initiate Insulin in Type 2 Diabetes. *Journal of Diabetes Science and Technology*. 2021. doi: 10.1177/1932296819900240
36. Ranjan A, Schmidt S, Nørgaard K. Glucagon for hypoglycaemia treatment in type 1 diabetes. *Diabetes/Metabolism Research and Reviews*. 2020. doi: 10.1002/dmrr.3409
37. Laugesen C, Ranjan A, Schmidt S, Rasmussen LN, Nørgaard O, Christensen R, Nørgaard K. Effect of adjunctive glucose-lowering drugs on body weight in people with type 1 diabetes: A systematic review and network meta-analysis protocol. *BMJ Open*. 2020. doi: 10.1136/bmjopen-2020-038970
38. Schmidt S, Nexø MA, Nørgaard O, Willaing I, Pedersen-Bjergaard U, Skinner TC, Nørgaard K. Psychosocial factors associated with HbA1c in adults with insulin pump-treated type 1 diabetes: a systematic review. *Diabetic Medicine*. 2020. doi: 10.1111/dme.14347
39. Dejgaard T, Schmidt S, Frandsen C, Vistisen D, Madsbad S, Andersen HU, Nørgaard K. Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial - a randomized, double-blinded, placebo-controlled trial. *Diabetes, Obesity & Metabolism*. 2020. doi: 10.1111/dom.13911
40. Laugesen C, Schmidt S, Tetzschner R, Nørgaard K, Ranjan A. Glucose Sensor Accuracy After Subcutaneous Glucagon Injections Near to Sensor Site. *Diabetes Technology & Therapeutics*. 2019. doi: 10.1089/dia.2019.0278
41. Tetzschner R, Ranjan A, Schmidt S, Nørgaard K. Preference for Subcutaneously Administered Low-Dose Glucagon Versus Orally Administered Glucose for Treatment of Mild Hypoglycemia: A Prospective Survey Study. *Diabetes Therapy*. 2019. doi: 10.1007/s13300-019-00696-x
42. Tikander E, Ranjan A, Schmidt S, Nørgaard K. Diabetic Ketoacidosis in A Person with Insulin Pump-Treated Type 1 Diabetes Mellitus while Following A Very Low Carbohydrate Diet – A Case Report. *Archives of Clinical and Medical Case Reports*. 3 (6) 418-421. 2019
43. Schmidt S, Christensen MB, Serifovski N, Damm-Frydenberg C, Jensen JEB, Fløyet T, Størling J, Ranjan A, Nørgaard K. Low versus High Carbohydrate Diet in Type 1 Diabetes: A 12-week randomized open-label crossover study. *Diabetes, Obesity & Metabolism*. 21 (7) 1680-1688. 2019
44. Steineck I, Mahmoudi Z, Ranjan A, Schmidt S, Jørgensen JB, Nørgaard K. Comparison of continuous glucose monitoring accuracy between abdominal and upper arm insertion sites. *Diabetes Technology & Therapeutics*. 21 (5) 295-302. 2019
45. Steineck I, Ranjan A, Schmidt S, Clausen TR, Holst JJ, Nørgaard K. Preserved glucose response to low-dose glucagon after exercise in insulin-pump-treated individuals with type 1 diabetes: a randomised crossover study. *Diabetologia*. 62 (4) 582-592. 2019
46. Ranjan A, Nørgaard K, Tetzschner R, Steineck I, Clausen TR, Holst JJ, Madsbad S, Schmidt S. Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals with Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study. *Diabetes Care*. 41 (4) 797-806. 2018
47. Ranjan A, Wendt SL, Schmidt S, Madsbad S, Holst JJ, Madsen H, Knudsen CB, Jørgensen JB, Nørgaard K. Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes – A Simulation Study. *Basic and Clinical Pharmacology and Toxicology*. 122 (3) 322-330. 2018
48. Boiroux D, Duun-Henriksen AK, Schmidt S, Nørgaard K, Madsbad S, Poulsen NK, Madsen H, Jørgensen JB. Overnight glucose control in type 1 diabetes. *Biomedical Signal Processing and Control*. 39 503-512. 2018
49. Schmidt S, Vistisen D, Almdal T, Hommel E, Nørgaard K. Exploring factors influencing HbA1c and psychosocial outcomes in people with type 1 diabetes after training in advanced carbohydrate counting. *Diabetes Research and Clinical Practice*. 130 (8) 61-66. 2017

50. Ranjan A, Schmidt S, Damm-Frydenberg C, Madsbad S, Holst J, Nørgaard K. Short-term Effects of Low Carbohydrate Diet on Glycaemic Parameters and Cardiovascular Risk Markers in Patients with Type 1 Diabetes – A Randomised Open-label Cross-over Trial. *Diabetes Obesity and Metabolism*. 19 (10) 1479-1484. 2017
51. Wendt SL, Ranjan A, Møller JK, Schmidt S, Knudsen CB, Holst JJ, Madsbad S, Madsen H, Nørgaard K, Jørgensen JB. Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes. *Journal of Diabetes Science and Technology*. 11 (6) 1101-1111. 2017
52. Mansell EJ, Schmidt S, Docherty PD, Nørgaard K, Jørgensen JB, Madsen H. Evaluation of pharmacokinetic model designs for subcutaneous infusion of insulin aspart. *Journal of Pharmacokinetics and Pharmacodynamics*. 44 (5) 477-489. 2017
53. Hommel E, Schmidt S, Vistisen D, Neergaard K, Gribhild M, Almdal T, Nørgaard K. Effects of advanced carbohydrate counting guided by an automated bolus calculator in type 1 diabetes mellitus (StenoABC): a 12-month, randomized clinical trial. *Diabetic Medicine*. 34 (5) 708-715. 2017
54. Schmidt S, Nørgaard K, Neergaard K, Almdal T, Hommel E. Long-Term Adherence to Automated Bolus Calculators. *Journal of Diabetes Science and Technology*. 11 (1) 174-175. 2017
55. Steineck I, Ranjan A, Nørgaard K, Schmidt S. Sensor-Augmented Insulin Pumps and Hypoglycemia Prevention in Type 1 Diabetes. *Journal of Diabetes Science and Technology*. 11 (1) 50-58. 2017
56. Ranjan A, Schmidt S, Damm-Frydenberg C, Steineck I, Clausen TR, Holst JJ, Madsbad S, Nørgaard K. Low carbohydrate diet impairs the effect of glucagon in the treatment of insulin-induced mild hypoglycemia: A randomized cross-over study. *Diabetes Care*. 40 (1) 132-135. 2017
57. Boiroux D, Duun-Henriksen AK, Schmidt S, Nørgaard K, Poulsen NK, Madsen H, Jørgensen JB. Adaptive control in an artificial pancreas for people with type 1 diabetes. *Control Engineering Practice*. 58 (1) 332-342. 2017
58. Nørgaard K, Schmidt S. Teknologiske behandlingsværktøjer til diabetes. *Ugeskrift for Læger*. 178 (50). 2016
59. Ranjan A, Schmidt S, Madsbad S, Holst JJ, Nørgaard K. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes. *Diabetes Obesity and Metabolism*. 18 (4) 410-418. 2016
60. Schmidt S, Boiroux D, Ranjan A, Jørgensen JB, Madsen H, Nørgaard K. An artificial pancreas for automated blood glucose control in patients with type 1 diabetes. *Therapeutic Delivery* 6 (5) 609-619. 2015
61. Meldgaard M, Damm-Frydenberg C, Vesth U, Nørgaard K, Schmidt S. Use of Advanced Carbohydrate Counting and an Automated Bolus Calculator in Clinical Practice – the BolusCal® training concept. *International Diabetes Nursing* 12 (1) 8-13. 2015
62. Reiband HK, Schmidt S, Ranjan A, Holst JJ, Madsbad S, Nørgaard K. Dual-hormone treatment with insulin and glucagon in patients with type 1 diabetes mellitus. *Diabetes/Metabolism Research and Reviews* 31 (7) 672-679. 2015
63. Schmidt S, Nørgaard K. Bolus Calculators. *Journal of Diabetes Science and Technology* 8 (5) 1035-1041. 2014
64. Schmidt S, Schelde B, Nørgaard K. Effects of Advanced Carbohydrate Counting in Patients with Type 1 Diabetes: A systematic review. *Diabetic Medicine*. 31 (8) 886-896. 2014
65. Hansen AH, Duun-Henriksen AK, Juhl R, Schmidt S, Nørgaard K, Jørgensen JB, Madsen H. Predicting Plasma Glucose From Interstitial Glucose Observations Using Bayesian Methods. *Journal of Diabetes Science and Technology*. 8 (2) 321-330. 2014
66. Schmidt S. New Technologies in the Treatment of Type 1 Diabetes. *Danish Medical Journal*. 60 (11) B4746. 2013
67. Schmidt S, Boiroux D, Duun-Henriksen AK, Frøssing L, Skyggebjerg O, Jørgensen JB, Poulsen NK, Madsen H, Madsbad S, Nørgaard K. Model-Based Closed-Loop Glucose Control in Type 1 Diabetes: The DiaCon Experience. *Journal of Diabetes Science and Technology*. 7 (5) 1255-1264. 2013

68. Duun-Henriksen AK, Schmidt S, Røge RM, Møller JB, Nørgaard K, Jørgensen JB, Madsen H. Model Identification Using Stochastic Differential Equation Grey-Box Models in Diabetes. *Journal of Diabetes Science and Technology*. 7 (2) 431-440. 2013
69. Schmidt S, Nørgaard K. Sensor-Augmented Pump Therapy at 36 Months. *Diabetes Technology & Therapeutics*. 14 (12) 1174-1177. 2012
70. Schmidt S, Duun-Henriksen AK, Nørgaard K. Psychosocial Factors and Adherence to Continuous Glucose Monitoring in Type 1 Diabetes. *Journal of Diabetes Science and Technology*. 6 (4) 986-987. 2012
71. Schmidt S, Meldgaard M, Serifovski N, Storm C, Christensen TM, Gade-Rasmussen B, Nørgaard K. Use of an Automated Bolus Calculator in MDI Treated Type 1 Diabetes: The BolusCal Study, a Randomized Controlled Pilot Study. *Diabetes Care*. 35 (5) 984-990. 2012
72. Schmidt S, Nørgaard K. Glucose Sensor Excludes Hypoglycaemia as Cause of Death. *Diabetes Research and Clinical Practice*. 96 (2) e30-e32. 2012
73. Schmidt S, Finan DA, Duun-Henriksen AK, Jørgensen JB, Madsen H, Bengtsson H, Holst JJ, Madsbad S, Nørgaard K. Effects of Every Day Life Events on Glucose, Insulin, and Glucagon Dynamics in Continuous Subcutaneous Insulin Infusion-Treated Type 1 Diabetes: Collection of Clinical Data for Glucose Modeling. *Diabetes Technology & Therapeutics*. 14 (3) 210-217. 2011
74. Secher AL, Schmidt S, Nørgaard K, Mathiesen ER. Continuous glucose monitoring-enabled insulin-pump therapy in diabetic pregnancy. *Acta Obstetrica et Gynecologica Scandinavica*. 89 (9) 1233-1237. 2010

Projects

Memberships

Other Relevant Information